441 related articles for article (PubMed ID: 27980305)
1. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
Dobashi A
J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
[TBL] [Abstract][Full Text] [Related]
2. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
3. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
[TBL] [Abstract][Full Text] [Related]
4. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
5. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
6. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
7. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
8. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
[TBL] [Abstract][Full Text] [Related]
9. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
10. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
[TBL] [Abstract][Full Text] [Related]
11. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
12. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
[TBL] [Abstract][Full Text] [Related]
13. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
14. Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy.
Jardin F
Discov Med; 2014; 18(97):51-65. PubMed ID: 25091488
[TBL] [Abstract][Full Text] [Related]
15. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
16. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.
Muppidi JR; Schmitz R; Green JA; Xiao W; Larsen AB; Braun SE; An J; Xu Y; Rosenwald A; Ott G; Gascoyne RD; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Vaidehi N; Staudt LM; Cyster JG
Nature; 2014 Dec; 516(7530):254-8. PubMed ID: 25274307
[TBL] [Abstract][Full Text] [Related]
17. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
18. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
[TBL] [Abstract][Full Text] [Related]
19. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP; Bagirov M; Du Y; Natkunam Y; Khoury HJ; Rossi MR; Harris W; Flowers CR; Lossos IS; Boise LH; Dave SS; Kowalski J; Bernal-Mizrachi L
Oncogene; 2017 Jul; 36(29):4224-4232. PubMed ID: 28368397
[TBL] [Abstract][Full Text] [Related]
20. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
